Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3)

Overview

Plain-Language Overview

Lymphogranuloma Venereum (LGV) is a sexually transmitted infection caused by certain types of the bacterium Chlamydia trachomatis (L1-L3). It primarily affects the lymphatic system and the genital area, leading to swollen and painful lymph nodes. The infection often starts with a small painless sore on the genitals that may go unnoticed. Over time, the nearby lymph nodes become enlarged and tender, sometimes forming abscesses or draining sores. If untreated, LGV can cause chronic swelling and scarring, which may lead to long-term complications such as genital deformities or rectal strictures. The disease mainly impacts the reproductive and lymphatic systems, affecting overall health by causing pain, swelling, and tissue damage.

Clinical Definition

Lymphogranuloma Venereum (LGV) is a chronic sexually transmitted infection caused by the invasive serovars L1, L2, and L3 of Chlamydia trachomatis. It is characterized by initial infection of the mucosal epithelium followed by spread to regional lymphatic vessels and nodes, causing lymphadenitis and lymphangitis. The disease progresses through stages: a primary painless genital ulcer, a secondary stage with painful inguinal or femoral lymphadenopathy (bubo formation), and a tertiary stage with chronic inflammation leading to fibrosis, strictures, and genital elephantiasis. LGV is significant due to its potential for severe local tissue destruction and systemic spread if untreated. Diagnosis and management are critical to prevent complications such as proctocolitis in men who have sex with men and chronic genital lymphedema.

Inciting Event

Exposure to Chlamydia trachomatis L1-L3 serovars through mucosal contact during sexual activity initiates infection.
Microabrasions in genital or rectal mucosa facilitate bacterial entry and infection.
Initial formation of a painless genital ulcer or papule at the site of inoculation.

Latency Period

Incubation period ranges from 3 to 30 days before primary lesion appears.
Lymphadenopathy typically develops 1 to 3 weeks after initial lesion.
Chronic symptoms may develop weeks to months later if untreated.

Diagnostic Delay

Painless primary lesion often goes unnoticed or is misdiagnosed as herpes or syphilis.
Lymphadenopathy may be mistaken for bacterial lymphadenitis or malignancy.
Limited availability of specific nucleic acid amplification tests (NAATs) delays confirmation.
Low clinical suspicion in non-endemic areas contributes to missed diagnosis.

Clinical Presentation

Signs & Symptoms

Painful inguinal lymphadenopathy (buboes) is the classic presenting symptom.
Genital or rectal ulcers often precede lymphadenopathy in the primary stage.
Fever and malaise commonly accompany the acute infection phase.
Rectal pain, discharge, and tenesmus occur in cases with proctitis.
Chronic genital swelling and fibrosis develop in untreated or late-stage disease.

History of Present Illness

Initial painless genital or rectal ulcer or papule that resolves spontaneously within days.
Subsequent painful inguinal or femoral lymphadenopathy (bubo formation) develops 1-3 weeks later.
Systemic symptoms such as fever, malaise, and headache may accompany lymphadenopathy.
Chronic proctocolitis symptoms including rectal pain, discharge, and bleeding occur in anorectal infection.
Late complications include genital elephantiasis and fistula formation if untreated.

Past Medical History

History of prior sexually transmitted infections (STIs) increases risk of LGV.
Previous episodes of genital ulcers or lymphadenopathy may suggest recurrent or untreated infection.
Immunosuppression, including HIV infection, can worsen disease severity and presentation.

Family History

[]

Physical Exam Findings

Tender inguinal lymphadenopathy often with fluctuant buboes is a hallmark of LGV.
Genital ulcers or papules may be present at the site of inoculation during the primary stage.
Proctitis with mucopurulent rectal discharge and rectal tenderness is common in receptive anal exposure.
Perianal ulcerations and fissures can be observed in advanced or chronic cases.
Elephantiasis of the genitalia may develop in late stages due to lymphatic obstruction.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of LGV is established by detecting L1-L3 serovars of Chlamydia trachomatis using nucleic acid amplification tests (NAATs) from lesion swabs or lymph node aspirates. Clinical suspicion arises with a history of painless genital ulcer followed by painful inguinal lymphadenopathy or proctitis symptoms. Confirmation requires identification of the specific LGV serovars, as routine chlamydia tests do not differentiate these. Additional supportive findings include bubo formation and characteristic proctocolitis on anoscopy or imaging. Serologic tests may assist but are less specific than molecular methods.

Pathophysiology

Key Mechanisms

Infection of lymphatic endothelial cells by Chlamydia trachomatis serovars L1-L3 leads to lymphatic inflammation and granulomatous reaction.
Intracellular replication of the bacteria causes cell-mediated immune response with recruitment of macrophages and T cells.
Lymphatic obstruction results from chronic inflammation causing lymphadenopathy and tissue fibrosis.
Ulceration of the primary lesion occurs due to local tissue necrosis and immune-mediated damage.

Involvement	Details
Organs	Inguinal lymph nodes are commonly involved, presenting as painful buboes due to granulomatous inflammation.
Organs	Genital mucosa serves as the initial site of Chlamydia trachomatis L1-L3 infection and ulcer formation.
Tissues	Lymphatic tissue is the primary site of granulomatous inflammation and lymphadenopathy characteristic of lymphogranuloma venereum.
Cells	Macrophages are the primary host cells infected by Chlamydia trachomatis L1-L3, facilitating bacterial replication and granuloma formation.
Cells	CD4+ T cells mediate the immune response leading to lymphadenitis and tissue inflammation in lymphogranuloma venereum.
Chemical Mediators	Interferon-gamma is critical for activating macrophages to control intracellular Chlamydia infection.
Chemical Mediators	Tumor necrosis factor-alpha (TNF-α) contributes to local inflammation and tissue damage in affected lymph nodes.

Treatments

Pharmacological Treatments

Doxycycline
- Mechanism:
  - Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit of Chlamydia trachomatis.
- Side effects:
  - Photosensitivity
  - Gastrointestinal upset
  - Tooth discoloration in children
- Clinical role:
  - First-line
Azithromycin
- Mechanism:
  - Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis in Chlamydia trachomatis.
- Side effects:
  - Gastrointestinal upset
  - QT prolongation
  - Hepatotoxicity
- Clinical role:
  - Alternative first-line

Non-pharmacological Treatments

Drainage of buboes via needle aspiration or incision and drainage to relieve painful lymphadenopathy.
Safe sexual practices and partner notification to prevent transmission and reinfection.

Prevention

Pharmacological Prevention

Doxycycline prophylaxis in high-risk populations can reduce LGV incidence.
Prompt antibiotic treatment of early chlamydial infections prevents progression to LGV.
Treatment of sexual partners with appropriate antibiotics to prevent reinfection.
Use of azithromycin as alternative therapy in doxycycline intolerance.
No vaccine currently available for LGV prevention.

Non-pharmacological Prevention

Consistent condom use significantly reduces transmission of Chlamydia trachomatis L1-L3.
Regular STI screening in high-risk populations enables early detection and treatment.
Partner notification and treatment to interrupt transmission chains.
Avoidance of high-risk sexual behaviors such as unprotected anal intercourse.
Education on genital hygiene and symptom recognition to promote early medical evaluation.

Outcome & Complications

Complications

Chronic lymphatic obstruction leading to genital elephantiasis.
Anal strictures and fistulas from chronic proctocolitis.
Abscess formation in inguinal lymph nodes requiring drainage.
Secondary bacterial infections of ulcerated skin or lymph nodes.
Infertility or chronic pelvic pain due to scarring in advanced disease.

Short-term Sequelae	Long-term Sequelae
Painful buboes and systemic symptoms such as fever and malaise during acute infection. Ulceration and mucosal inflammation at the site of inoculation. Proctitis with rectal bleeding and discharge in cases involving the rectum. Lymphadenitis with possible abscess formation requiring intervention. Transient genital swelling and erythema during acute inflammation.	Genital elephantiasis from chronic lymphatic obstruction and fibrosis. Anal strictures and chronic proctitis causing persistent pain and defecation difficulties. Fistula formation between rectum and perineum or vagina. Chronic pelvic pain and sexual dysfunction due to scarring. Psychosocial impact from disfigurement and chronic symptoms.

Differential Diagnoses

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3) versus Herpes Simplex Virus (HSV) Infection

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3)	Herpes Simplex Virus (HSV) Infection
Painless or mildly painful small papule or ulcer that progresses to tender inguinal lymphadenopathy	Painful vesicular genital ulcers that rupture to form shallow ulcers
Unilateral or bilateral tender inguinal lymphadenopathy with suppuration (bubo formation)	Bilateral tender inguinal lymphadenopathy often without suppuration
Positive nucleic acid amplification test (NAAT) for Chlamydia trachomatis L1-L3 serovars	Positive PCR or viral culture for HSV DNA

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3) versus Syphilis (Treponema pallidum)

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3)	Syphilis (Treponema pallidum)
Small, often painful papule or ulcer with tender lymphadenopathy	Painless, indurated chancre at inoculation site
Suppurative, unilateral or bilateral buboes	Non-suppurative, rubbery, bilateral lymphadenopathy
Positive NAAT for Chlamydia trachomatis L1-L3	Positive darkfield microscopy or treponemal serology

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3) versus Chancroid (Haemophilus ducreyi)

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3)	Chancroid (Haemophilus ducreyi)
Small, painless or mildly painful papule or ulcer with tender lymphadenopathy	Painful, soft, ragged genital ulcers with undermined edges
Unilateral or bilateral tender buboes, often with suppuration	Unilateral, painful suppurative inguinal lymphadenopathy (bubo)
NAAT positive for Chlamydia trachomatis L1-L3	Culture positive for Haemophilus ducreyi

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3) versus Granuloma Inguinale (Donovanosis)

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3)	Granuloma Inguinale (Donovanosis)
Small papule or ulcer with tender inguinal lymphadenopathy and bubo formation	Painless, beefy-red granulomatous ulcerative lesions without lymphadenopathy
Prominent tender suppurative inguinal lymphadenopathy	Typically absent or minimal lymphadenopathy
Positive NAAT for Chlamydia trachomatis L1-L3	Identification of Donovan bodies on tissue smear

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3) versus Tuberculous Lymphadenitis

Lymphogranuloma Venereum (LGV) (Chlamydia trachomatis L1-L3)	Tuberculous Lymphadenitis
Acute to subacute tender suppurative inguinal lymphadenopathy	Chronic, painless, firm lymphadenopathy often with caseating granulomas
Systemic symptoms usually absent or mild	Constitutional symptoms like fever, night sweats, weight loss common
Positive NAAT for Chlamydia trachomatis L1-L3	Positive acid-fast bacilli stain or culture from lymph node biopsy